Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR) announced top-line 24-week data demonstrating persistent migraine prevention in a Phase 2b clinical trial evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE